Abhinav V Reddy1, Joseph J Pariser2, Shane M Pearce2, Ralph R Weichselbaum1, Norm D Smith2, Gary D Steinberg2, Stanley L Liauw3. 1. Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois. 2. Section of Urology, Department of Surgery, University of Chicago Pritzker School of Medicine, Chicago, Illinois. 3. Department of Radiation and Cellular Oncology, University of Chicago Pritzker School of Medicine, Chicago, Illinois. Electronic address: sliauw@radonc.uchicago.edu.
Abstract
PURPOSE: In patients with muscle-invasive bladder cancer, local-regional failure (LF) has been reported to occur in up to 20% of patients following radical cystectomy. The goals of this study were to describe patterns of LF, as well as assess factors associated with LF in a cohort of patients with pT3-4 bladder cancer. This information may have implications towards the use of adjuvant radiation therapy. METHODS AND MATERIALS: Patients with pathologic T3-4 N0-1 bladder cancer were examined from an institutional radical cystectomy database. Preoperative demographics and pathologic characteristics were examined. Outcomes included overall survival and LF. Local-regional failures were defined using follow-up imaging reports and scans, and the locations of LF were characterized. Variables were tested by univariate and multivariate analysis for association with LF and overall survival. RESULTS: A total of 334 patients had pT3-4 and N0-1 disease after radical cystectomy and bilateral pelvic lymph node dissection. Of these, 46% received perioperative chemotherapy. The median age was 71 years old, and median follow-up was 11 months. On univariate analysis, margin status, pT stage, and pN stage, were all associated with LF (P<.05), however, on multivariate analysis, only pT and pN stages were significantly associated with LF (P<.05). Three strata of risk were defined, including low-risk patients with pT3N0 disease, intermediate-risk patients with pT3N1 or pT4N0 disease, and high-risk patients with pT4N1 disease, who had a 2-year incidence of LF of 12%, 33%, and 72%, respectively. The most common sites of pelvic relapse included the external and internal iliac lymph nodes (LNs) and obturator LN regions. Notably, 34% of patients with LF had local-regional only disease at the time of recurrence. CONCLUSIONS: Patients with pT4 or N1 disease have a 2-year risk of LF that exceeds 30%. These patients may be the most likely to benefit from local adjuvant therapies.
PURPOSE: In patients with muscle-invasive bladder cancer, local-regional failure (LF) has been reported to occur in up to 20% of patients following radical cystectomy. The goals of this study were to describe patterns of LF, as well as assess factors associated with LF in a cohort of patients with pT3-4 bladder cancer. This information may have implications towards the use of adjuvant radiation therapy. METHODS AND MATERIALS: Patients with pathologic T3-4 N0-1 bladder cancer were examined from an institutional radical cystectomy database. Preoperative demographics and pathologic characteristics were examined. Outcomes included overall survival and LF. Local-regional failures were defined using follow-up imaging reports and scans, and the locations of LF were characterized. Variables were tested by univariate and multivariate analysis for association with LF and overall survival. RESULTS: A total of 334 patients had pT3-4 and N0-1 disease after radical cystectomy and bilateral pelvic lymph node dissection. Of these, 46% received perioperative chemotherapy. The median age was 71 years old, and median follow-up was 11 months. On univariate analysis, margin status, pT stage, and pN stage, were all associated with LF (P<.05), however, on multivariate analysis, only pT and pN stages were significantly associated with LF (P<.05). Three strata of risk were defined, including low-risk patients with pT3N0 disease, intermediate-risk patients with pT3N1 or pT4N0 disease, and high-risk patients with pT4N1 disease, who had a 2-year incidence of LF of 12%, 33%, and 72%, respectively. The most common sites of pelvic relapse included the external and internal iliac lymph nodes (LNs) and obturator LN regions. Notably, 34% of patients with LF had local-regional only disease at the time of recurrence. CONCLUSIONS:Patients with pT4 or N1 disease have a 2-year risk of LF that exceeds 30%. These patients may be the most likely to benefit from local adjuvant therapies.
Authors: Mohamed S Zaghloul; John P Christodouleas; Andrew Smith; Ahmed Abdallah; Hany William; Hussein M Khaled; Wei-Ting Hwang; Brian C Baumann Journal: JAMA Surg Date: 2018-01-17 Impact factor: 14.766
Authors: Zhoobin H Bateni; Shane M Pearce; Daniel Zainfeld; Leslie Ballas; Hooman Djaladat; Anne K Schuckman; Siamak Daneshmand Journal: Eur Urol Oncol Date: 2018-12-19
Authors: Brian C Baumann; Paul Sargos; Libni J Eapen; Jason A Efstathiou; Ananya Choudhury; Amit Bahl; Vedang Murthy; Leslie K Ballas; Valérie Fonteyne; Pierre M Richaud; Mohamed S Zaghloul; John P Christodouleas Journal: Bladder Cancer Date: 2017-01-27
Authors: Valérie Fonteyne; Piet Dirix; Sara Junius; Elke Rammant; Piet Ost; Gert De Meerleer; Martijn Swimberghe; Karel Decaestecker Journal: BMC Cancer Date: 2017-05-02 Impact factor: 4.430
Authors: Benjamin W Fischer-Valuck; Jeff M Michalski; Nandita Mitra; John P Christodouleas; Todd A DeWees; Eric Kim; Zachary L Smith; Gerald L Andriole; Vivek Arora; Arnold Bullock; Ruben Carmona; Robert S Figenshau; Robert L Grubb; Thomas J Guzzo; Eric M Knoche; S Bruce Malkowicz; Ronac Mamtani; Russell K Pachynski; Bruce J Roth; Mohamed S Zaghloul; Hiram A Gay; Brian C Baumann Journal: Cancer Med Date: 2019-05-22 Impact factor: 4.452
Authors: Nikhil V Kotha; Abhishek Kumar; Tyler J Nelson; Edmund M Qiao; Alex S Qian; Rohith S Voora; Rana R McKay; Brent S Rose; Tyler F Stewart Journal: Urol Oncol Date: 2022-02-23 Impact factor: 2.954